These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9323304)

  • 1. Prevent hyperphosphatemia in a child on hemodialysis.
    Drukker A
    Pediatr Nephrol; 1997 Oct; 11(5):661. PubMed ID: 9323304
    [No Abstract]   [Full Text] [Related]  

  • 2. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia.
    Fournier A; Moriniere P; Sebert JL; Dkhissi H; Atik A; Leflon P; Renaud H; Gueris J; Gregoire I; Idrissi A
    Kidney Int Suppl; 1986 Feb; 18():S114-9. PubMed ID: 3457987
    [No Abstract]   [Full Text] [Related]  

  • 3. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 4. Calcium carbonate as a phosphate binder.
    N Engl J Med; 1987 Jan; 316(2):109-10. PubMed ID: 3785355
    [No Abstract]   [Full Text] [Related]  

  • 5. Correction of hypercalcemia and hypophosphatemia by hemodialysis using a conventional, calcium-containing dialysis solution enriched with phosphorus.
    Leehey DJ; Ing TS
    Am J Kidney Dis; 1997 Feb; 29(2):288-90. PubMed ID: 9016904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [2 dialysis cases which came to our clinic for the symptoms caused by hypercalcemia].
    Shin J; Nishioka M; Shinko S; Yamamoto T; Shibuya K; Kasumoto H; Bito Y; Fujita Y; Komaba K
    Clin Calcium; 2005 Sep; 15 Suppl 1():87-91; discussion 91. PubMed ID: 16272638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Life-threatening milk-alkali syndrome resulting from antacid ingestion during pregnancy.
    Tran HA
    Med J Aust; 2005 Jun; 182(12):654; author reply 655. PubMed ID: 15963028
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of calcium carbonate in dialysis patients with hypercalcemia.
    Verhelst JA; Van den Enden EJ; Zachée P; Daelemans RA; Lins RL
    Clin Nephrol; 1988 Nov; 30(5):287. PubMed ID: 3214973
    [No Abstract]   [Full Text] [Related]  

  • 10. [Role of calcium carbonate in the treatment of renal osteodystrophy].
    Morinière P; Boudailliez B; Westeel PF; Achard JM; Djerad M; Nahle M; Amar M; Fournier A
    Nephrologie; 1991; 12(1):31-41. PubMed ID: 2034319
    [No Abstract]   [Full Text] [Related]  

  • 11. The treatment of uremic hyperphosphatemia.
    Schaefer K
    Clin Nephrol; 1996 Oct; 46(4):279-80. PubMed ID: 8905221
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis.
    Salusky IB; Coburn JW; Foley J; Nelson P; Fine RN
    J Pediatr; 1986 May; 108(5 Pt 1):767-70. PubMed ID: 3701525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
    Iwasaki Y; Takami H; Tani M; Yamaguchi Y; Goto H; Goto Y; Goto Y; Shigematsu T
    Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colonic intussusception secondary to a calcium phosphate bezoar in a child receiving calcium carbonate for hyperphosphatemia.
    Fildes RD; Springate JE; Jewett T; O'Shea MM; Feld LG
    J Pediatr Surg; 1989 Nov; 24(11):1195-7. PubMed ID: 2809998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypercalcemia with calcium carbonate for uraemic hyperparathyroidism: consequence of a challenge overmet by the nephrologist?
    Fournier A
    Nephrol Dial Transplant; 1993; 8(2):188-9. PubMed ID: 8384346
    [No Abstract]   [Full Text] [Related]  

  • 18. Calcium carbonate: a suitable alternative to aluminum hydroxide as phosphate binder.
    Malberti F; Surian M; Colussi G; Poggio F; Minoia C; Salvadeo A
    Kidney Int Suppl; 1988 Mar; 24():S184-5. PubMed ID: 3163047
    [No Abstract]   [Full Text] [Related]  

  • 19. Control of secondary hyperparathyroidism during long-term hemodialysis.
    Goldsmith RS; Furszyfer J; Johnson WJ; Fournier AE; Arnaud CD
    Am J Med; 1971 May; 50(5):692-9. PubMed ID: 5575551
    [No Abstract]   [Full Text] [Related]  

  • 20. Calcium carbonate treatment of uremic acidosis.
    Berlyne GM
    Isr J Med Sci; 1971 Nov; 7(11):1235-9. PubMed ID: 5159605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.